11 assets in Invasive Lobular Breast Carcinoma

Therapeutic assets addressing Invasive Lobular Breast Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Fulvestrant Invasive Lobular Breast Carcinoma	M.D. Anderson Cancer Center	P3	BB (65)
Anastrozole Invasive Lobular Breast Carcinoma	Alliance for Clinical Trials in Oncology	P3	B (60)
Fes F-18 Invasive Lobular Breast Carcinoma	Asan Medical Center	P2	B (56)
FAPI74 Invasive Lobular Breast Carcinoma	Randy Yeh	P2	CCC (53)
Fludeoxyglucose Invasive Lobular Breast Carcinoma	Randy Yeh	P2	CCC (53)
Neratinib Invasive Lobular Breast Carcinoma	Vanderbilt-Ingram Cancer Center	P2	CCC (53)
Repotrectinib Invasive Lobular Breast Carcinoma	M.D. Anderson Cancer Center	P2	CCC (52)
[18F]FPyQCP Invasive Lobular Breast Carcinoma	Blue Earth Diagnostics	P1/2	CCC (48)
68ga-dfc413 Invasive Lobular Breast Carcinoma	Novartis Pharmaceuticals	P1	CC (43)
68Ga-NNS309 Invasive Lobular Breast Carcinoma	Novartis Pharmaceuticals	P1	CC (43)
[68Ga]Ga DOTA-5G Invasive Lobular Breast Carcinoma	University of California, Davis	P1	NR ()